Pierre-Olivier Fiset
Overview
Explore the profile of Pierre-Olivier Fiset including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desharnais L, Sorin M, Rezanejad M, Liu B, Karimi E, Atallah A, et al.
Nat Commun
. 2025 Feb;
16(1):1345.
PMID: 39905080
Lung cancer is the leading cause of cancer-related deaths. An enhanced understanding of the immune microenvironments within these tumours may foster more precise and efficient treatment, particularly for immune-targeted therapies....
2.
Alirezaie N, Chong A, Kommoss F, Sabbaghian N, Camacho Valenzuela J, Pelletier D, et al.
Lung Cancer
. 2024 Aug;
195:107916.
PMID: 39121796
Objective: Pulmonary blastoma is a rare, biphasic, adult-onset lung tumor. In this study, we investigate whether DICER1 pathogenic variants are a feature of pulmonary blastomas through in-depth analysis of the...
3.
Pilon Y, Rokah M, Seitlinger J, Sepesi B, Rayes R, Cools-Lartigue J, et al.
Clin Lung Cancer
. 2024 Feb;
25(3):e133-e144.e4.
PMID: 38378398
Background: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents...
4.
Chong A, Thorner P, Ellis M, Swensen J, Benlimame N, Fiset P, et al.
Am J Surg Pathol
. 2023 Dec;
48(2):221-229.
PMID: 38050371
Germline and somatic pathogenic variants (PVs) in DICER1 , encoding a miRNA biogenesis protein, are associated with a wide variety of highly specific pathologic entities. The lung tumors pleuropulmonary blastoma,...
5.
Fiset P, Bigras G
Appl Immunohistochem Mol Morphol
. 2023 Jul;
31(8):531-532.
PMID: 37493457
No abstract available.
6.
Tankel J, Mouhanna J, Katz A, Fiset P, Rayes R, Siblini A, et al.
Clin Lung Cancer
. 2023 May;
24(6):551-557.
PMID: 37258384
Introduction: Whilst the American Joint Committee on Cancer 7th edition (AJCC7) classified pT4 non-small-cell lung cancers (NSCLC) as those with extra-pulmonary invasion, the revised 8th edition (AJCC8) included tumors >...
7.
Alsaddah S, Papadakis A, Wong N, Palma L, Szlachtycz D, Marino T, et al.
Lung Cancer
. 2023 May;
181:107247.
PMID: 37209596
Background: Somatic epidermal growth factor receptor (EGFR) pathogenic variants have been identified and are routinely tested in the molecular diagnosis of non-small cell lung cancer (NSCLC) as they represent a...
8.
Golesworthy B, Wang Y, Tanti A, Pacis A, Romero J, Cuggia A, et al.
Front Oncol
. 2022 May;
12:860767.
PMID: 35547873
The immune contexture of pancreatic ductal adenocarcinoma (PDAC) is generally immunosuppressive. A role for immune checkpoint inhibitors (ICIs) in PDAC has only been demonstrated for the rare and hypermutated mismatch...
9.
Baig A, Albrecht S, Gomez Corredor A, Fiset P, Chen M
Pediatr Dev Pathol
. 2022 Apr;
25(4):479-484.
PMID: 35421319
Congenital Langerhans cell histiocytosis (LCH) (formerly called Letterer-Siwe disease) is characterized by a clonal proliferation of Langerhans cells occurring in children at birth and manifests typically with multifocal cutaneous lesions,...
10.
Kidane B, Spicer J, Kim J, Fiset P, Abdulkarim B, Malthaner R, et al.
Front Oncol
. 2020 Oct;
10:580189.
PMID: 33072612
Surgical resection is the standard-of-care approach for early-stage non-small cell lung cancer (NSCLC). Surgery is also considered an acceptable standard infit patients with oligometastatic lesions in the lungs. The COVID-19...